Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) is a prescription medicine that is used to treat certain muscle and nerve conditions. It is a combination of two medicines, efgartigimod alfa and ...
Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for demyelinating ...
Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...
Victoria Johnston, 35, was fit and healthy when she collapsed at work in 2022 and was unable to feel her legs beneath her ...
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration ...
The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). "This medication has a novel ...
Victoria Johnston, 35, from Milton Keynes says her life was turned upside down after she collapsed at work and was unable to ...
Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback